![Sonicated DNA was prepared from yeast strain (No-247) BY4742 treated with Cisplatin (2.5 mM; 4 hour incubation). Immunoprecipitation was performed using an increasing amount of anti-Cisplatin modified DNA [CP9/19] (top panel) and anti-Cisplatin modified DNA; Recombinant [CP9/19] (lower panel). Fold enrichment over no antibody control is shown on the Y axis with the amount of antibody indicated (in ug) on the X axis. Data kindly provided by Drs. Simon Reed and Shuvro Prokash Nandi.](https://cancertools.org/wp-content/uploads/45302546-aa2c-4b57-b0a6-546b671978b3.jpg "45302546-aa2c-4b57-b0a6-546b671978b3.jpg")
Cat. #152732
Anti-Cisplatin modified DNA [CP9/19]
Cat. #: 152732
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Cisplatin modified native DNA
Class: Recombinant
Application: ELISA ; IHC ; IP ; DB
Host: Rat
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Michael Tilby
Institute: Absolute Antibody ; Newcastle University ; The Institute of Cancer Research
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-Cisplatin modified DNA [CP9/19]
- Clone: rCP9/19
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Host: Rat
- Application: ELISA ; IHC ; IP ; DB
- Description: This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
- Isotype: IgG2a kappa
- Recommended controls: RNA/DNA
Target Details
- Target: Cisplatin modified native DNA
- Tissue cell line specificity: RNA/DNA
- Target background: This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
Applications
- Application: ELISA ; IHC ; IP ; DB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
Related Tools
- Related tools: Anti-Cisplatin modified DNA [CP9/19]
References
- Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
- Original hybridoma first published in: Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.
